CytomX(CTMX) - 2024 Q1 - Quarterly Results

Exhibit 99.1 CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T- cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY® ADC, in solid tumors. Initial data anticipated in the first half of 2025 - - Phase 1 study initiation activities continue for CX-801, an interferon alpha-2b PROBODY® cytokine, ...